Seminars in Nuclear Medicine
Volume 33, Issue 3 , Pages 238-243 , July 2003

Role of fusion in radiotherapy treatment planning

References 

  1. Ling CC, Humm J, Larson S, et al.  Towards multidimensional radiotherapy (MD-CRT): Biological imaging and biological conformality. Int J Radiat Oncol Biol Phys. 2000;47:551–560
  2. Tepper J. Form and function: The integration of physics and biology. Int J Radiat Oncol Biol Phys. 2000;47:547–548
  3. Marks LB, Spencer DP, Bentel GB, et al.  The utility of SPECT lung perfusion scans in minimizing and assessing the physiological consequences of thoracic irradiation. Int J Radiat Oncol Biol Phys. 1993;26:659–668
  4. Marom EM, McAdams HP, Erasmus JJ, et al.  Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803–809
  5. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al.  Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med. 2000;343:254–261
  6. Higashi K, Ueda Y, Seki H, et al.  Fluorine-18-FDG PET imaging is negative in bronchoalveolar lung carcinoma. J Nucl Med. 1998;39:1016–1020
  7. Webb WR, Gatsonis C, Zerhouni EA, et al.  CT and MR in staging non-small cell bronchogenic carcinoma—Report of the Radiologic Diagnostic Oncology Group. Radiology. 1991;178:705–713
  8. Dwamena BA, Sonnad SS, Angobaldo JO, et al.  Metastases from non-small cell lung cancer: Mediastinal staging in the 1990s—Meta-analytic comparison of PET and CT. Radiology. 1999;213:530–536
  9. Erasmus JJ, Patz EF, McAdams HP, et al.  Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR. 1997;168:1357–1360
  10. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (<1 cm), intermediate (1 to 3 cm) and large (>3 cm) lymph node lesions. Chest. 2000;117:773–778
  11. Bury T, Paulus P, Dowlati A, et al.  Evaluation of pleural diseases with PDG-PET imaging: Preliminary report. Thorax. 1997;52:187–189
  12. Tucker R, Coel M, Ko J, et al.  Impact of fluorine-18 fluorodeoxyglucose positron emission tomography on patient management: First year's experience in a clinical center. J Clin Oncol. 2001;19:2504–2508
  13. MacManus MP, Wong K, Hicks RJ, et al.  Early mortality after radical radiotherapy for non-small-cell lung cancer: Comparison of PET-staged and conventionally staged cohorts treated at a large tertiary referral center. Int J Radiat Oncol Biol Phys. 2002;52:351–361
  14. Robertson JM, Ten Haken RK, Hazuka MB, et al.  Dose escalation for non-small cell lung cancer using conformal radiation therapy. Int J Radiat Oncol Biol Phys. 1997;7:1079–1085
  15. Graham MV, Purdy JA, Emami B, et al.  Preliminary results of a prospective trial using three dimensional radiotherapy for lung cancer. Int J Radiat Oncol Biol Phys. 1995;33:993–1000
  16. Armstrong J, Raben A, Zelefsky M, et al.  Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997;44:17–22
  17. Kiffer JD, Berlangieri SU, Scott AM, et al.  The contribution of 18F-fluoro-2-deoxy-glucose positron emission tomographic imaging to radiotherapy planning in lung cancer. Lung Cancer. 1998;19:167–177
  18. Nestle U, Walter K, Schmidt S, et al.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: High impact in patients with atelectasis. Int J Radiat Oncol Biol Phys. 1999;44:593–597
  19. Erdi YE, Rosenzweig K, Erdi AK, et al.  Radiotherapy treatment planning for patients with non-small cell lung cancer using positron emission tomography (PET). Radiother Oncol. 2002;62:51–60
  20. Vanuytsel LJ, Vansteenkiste JF, Stroobants SG, et al.  The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer. Radiother Oncol. 2000;55:317–324
  21. Mah K, Caldwell CB, Ung YC, et al.  The impact of 18FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small cell lung carcinoma: A prospective study. Int J Radiat Oncol Biol Phys. 2002;52:339–350
  22. Kalff V, Hicks RJ, MacManus MP, et al.  Clinical impact of 18F fluorodeoxyglucose positron emission tomography in patients with non-small cell lung cancer: A prospective study. J Clin Oncol. 2001;19:111–118
  23. Yorke ED, Jackson A, Rosenweig KE, et al.  Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys. 2002;54:329–339
  24. Graham MV, Purdy JA, Emami B, et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323–329
  25. Schmuecking M, Baum RP, Bonnet R, et al: F-18 FDG PET and its potential in therapeutic management and 3-D radiation treatment planning of non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 54(S):33
  26. Beitler JJ. Unsubstantiated conclusions can impede progress in lung cancer. Int J Radiat Oncol Biol Phys. 2000;46:1337
  27. Caldwell CB, Mah K, Ung YC, et al.  Observer variation in contouring gross tumor volume in patients with poorly defined non-small cell lung tumors on CT: The impact of 18FDG-hybrid PET fusion. Int J Radiat Oncol Biol Phys. 2001;51:923–931
  28. Marks LB, Spencer DP, Sherouse GW, et al.  The role of three-dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram. Int J Radiat Oncol Biol Phys. 1995;33:65–75
  29. Munley MT, Marks LB, Scarfone C, et al.  Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. Lung Cancer. 1999;23:105–114
  30. Seppenwoolde Y, Engelsman M, DeJaeger K, et al.  Optimizing radiation treatment plans for lung cancer using lung perfusion information. Radiother Oncol. 2002;63:165–177
  31. Scifter T, Hoffman JM, Hanson MW, et al.  Serial FDG-PET studies in the prediction of survival in patients with primary brain tumors. J Comput Assist. 1993;17:509
  32. Thornton AF, Sandler HM, Ten Haken RK, et al.  The clinical utility of magnetic resonance imaging in 3-dimensional treatment planning of brain neoplasms. Int J Radiat Oncol Biol Phys. 1992;24:767–775
  33. Gross MW, Weber WA, Feldmann HJ, et al.  The value of F-18-fluorodeoxyglucose PET for the 3-D radiation treatment planning of malignant gliomas. Int J Radiat Oncol Biol Phys. 1998;41:989–995
  34. Pardo FS, Aronen HJ, Kennedy D, et al.  Functional cerebral imaging in the evaluation and radiotherapeutic treatment planning of patients with malignant glioma. Int J Radiat Oncol Biol Phys. 1994;30:663–669
  35. Levivier M, Wikier D, Goldman S, et al.  Integration of the metabolic data of positron emission tomography in the dosimetry planning of radiosurgery with the gamma knife: Early experience with brain tumors. J Neurosurg. 2000;93(S):233–238
  36. Ericson K, Lilja A, Bergstrom M, et al.  Positron emission tomography (11C methyl)-L-methionine, (11C) D-glucose, and (68Ga) EDTA in supratentorial tumors. J Comput Assist Tomograph. 1985;9:683–689
  37. Kaschten B, Stevenaert A, Sadzot B, et al.  Preoperative evaluation of 54 gliomas by PET with fluorodeoxyglucose and/or carbon-11-methionine. J Nucl Med. 1998;39:778–785
  38. Nuutinen J, Sonninen P, Lehikoinen P, et al.  Radiotherapy treatment planning and long-term follow-up with (11C) methionine PET in patients with low-grade astrocytoma. Int J Radiat Oncol Biol Phys. 2000;48:43–52
  39. Hamilton RJ, Sweeney PJ, Pelizzari CA, et al.  Functional imaging in treatment planning of brain lesions. Int J Radiat Oncol Biol Phys. 1997;37:181–188
  40. Grosu AL, Weber W, Feldmann HJ, et al.  First experience with I-123-alpha-methyl-tyrosine SPECT in the 3-D radiation treatment planning of brain gliomas. Int J Radiat Oncol Biol Phys. 2000;47:517–526
  41. Grosu AL, Feldmann HJ, Dick S, et al.  Implications of IMT-SPECT for postoperative radiotherapy planning in patients with gliomas. Int J Radiat Oncol Biol Phys. 2002;54:842–854
  42. McGuirt WF, Greven KM, Keyes JW, et al.  Positron emission tomography in the evaluation of laryngeal carcinoma. Ann Otol Rhinol Laryngol. 1995;104:274–278
  43. McGuirt WF, Williams D, Keyes JW, et al.  A comparative diagnostic study of head and neck nodal metastases using positron emission tomography. Laryngoscope. 1995;105:373–375
  44. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al.  Comparison of Fluorine-18Fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck squamous cell carcinoma. J Nucl Med. 1995;36:1747–1757
  45. McGuirt WF, Keyes JW, Greven KW, et al.  Preoperative identification of benign versus malignant parotid masses: A comparative study including positron emission tomography. Laryngoscope. 1995;105:579–584
  46. Nishioka T, Shiga T, Shirato H, et al.  Image fusion between 18FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys. 2002;53:1051–1057
  47. Daisne J, Duprez T, Weynant B, et al: Impact of image coregistration with computed tomography (CT), magnetic resonance (MR) and positron emission tomography with fluorodeoxyglucose (FDG-PET) on delineation of GTV's in oropharyngeal, laryngeal and hypopharyngeal tumors. Int J Radiat Oncol Biol Phys 54(S):15
  48. Chao KSC, Bosch WR, Mutic S, et al.  A novel approach to overcome hypoxic tumor resistance: Cu-ATSM-guided intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys. 2001;49:1171–1182
  49. Aassar OS, Fishbein N, Caputo GR, et al.  Metastatic head and neck cancer: Role and usefulness of FDG PET in locating occult primary tumors. Radiology. 1999;210:177–181
  50. Jungehulsing M, Scheidhauer K, Pietrzyk U, et al.  Detection of unknown primary with fluoro-deoxy-glucose positron emission tomography. Ann Otol Rhinol Laryngol. 1999;108:623–626
  51. Grigsby PW, Siegel BA, Dehdashti F, et al.  Lymph node staging by positron emission tomography in patients with carcinoma of the cervix. J Clin Oncol. 2001;19:3745–3749
  52. Miller TR, Grigsby PW. Measurement of tumor volume by PET to evaluate prognosis in patients with advanced cervical cancer treated by radiation therapy. Int J Radiat Oncol Biol Phys. 2002;53:353–359
  53. Paul R. Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. J Nucl Med. 1987;28:288
  54. Valk PE, Pounds TR, Tesar RD, et al.  Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol. 1996;23:737–743

☆ Address reprint requests to Arnold C. Paulino, MD, Emory Clinic, Department of Radiation Oncology, 1365 Clifton Road NE, A1300, Atlanta, GA 30322.

☆☆ 0001-2998/03/3303-0017$30.00/0

PII: S0001-2998(03)70009-9

doi: 10.1053/snuc.2003.127313

Seminars in Nuclear Medicine
Volume 33, Issue 3 , Pages 238-243 , July 2003

Article Tools